Australian-based and globally integrated biopharmaceutical company, Immuron Ltd (NASDAQ:IMRN, ASX:IMC), will present at The Military Health System Research Symposium (MHSRS), in Kissimmee, Florida from August 14-17, 2023.
The MHSRS is the US Department of Defense’s premier scientific meeting that focuses specifically on the unique medical needs of troops.
Infectious diarrhea is the most common illness reported by US troops deployed overseas. The company’s Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller’s diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
As such, Immuron says the annual symposium will be a good networking opportunity as it brings together nearly 3,000 healthcare professionals, researchers, US Department of Defense leaders and decision-makers as well as various funding bodies.
Immuron will attend the meeting as an exhibitor and present two posters at the event, one of which is titled, 'Clinical Evaluation of an Oral prophylactic for prevention of Travellers diarrhea in active-duty military assigned abroad'.
Getting the message out
The company has also been invited by the Medical Technology Enterprise Consortium (MTEC) to showcase Immuron and its collaborative work with the US Department of Defence including an overview of the current MTEC award titled 'Biologics licence application of a bovine immunoglobulin supplement that prevents travellers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC)'.
The Naval Medical Research Center (NMRC) is also presenting a poster at the symposium on the new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC poster is titled 'Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travellers’ Diarrhea'.
The presentations are available on Immuron’s website: https://www.immuron.com.au/product-science/
- by Meagan Evans